The executive director of the Institute for Translational Research at UNT Health discussed how to increase representation of underrepresented groups in Alzheimer disease clinical trials. [WATCH TIME: 5 minutes]
Sid O’Bryant, PhD
Advertisement
Executive director of the Institute for Translational Research at UNT Health.
Articles by Sid O’Bryant, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
CTAD Presentation Lays Insights Into Disappointing Phase 3 EVOKE Trial of GLP-1 Semaglutide in Alzheimer Disease
2
NeuroVoices: Robert Alexander, MD, on the Evolution of Antiamyloid Therapeutics in Alzheimer Disease
3
Neflamapimod Reduces Plasma GFAP in Dementia With Lewy Bodies, Showing Correlation With Clinical Improvement
4
Additional Insights From the U.S. POINTER Study at CTAD 2025: Heather M. Snyder, PhD
5
